Business
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, May 13, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, May 13, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (\"Kintara\" or the \"Company\"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2022 and provided a corporate update.\n\n \n \n \n \n \n \n\n \nCORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTSClosed a registered direct financing with certain institutional investors pursuant to which the Company received approximately $7.9 million in net proceeds after deducting placement agent fees and other offering expenses payable by the Company (April).Received notice of the U.S. Patent and Trademark Office's issuance of United States Patent No. 11,234,955 to VAL-083 covering a method of treating brain tumors including glioblastoma multiforme (GBM), medulloblastoma, and cancer brain tumor stem cells that has O6-methyl guanine methyltransferase (MGMT)-driven drug resistance (February).Announced that the Global Coalition for Adaptive Research (GCAR) GBM Adaptive Global Innovative Learning Environment (AGILE) registrational Phase 2/3 clinical study (GBM AGILE Study) has screened over 1,000 patients and that enrollment rates for the study are 3 to 4 times greater than traditional GBM studies according to GCAR, with active sites averaging 0.75 to 1 patient per site per month. As a result of the accelerated enrollment rate, the Company expects to announce top-line data from the Kintara arm of the study around the end of calendar year 2023 (January).Continued to advance development of REM-001 for the treatment of Cutaneous Metastatic Breast Cancer (CMBC), including taking critical steps toward manufacturing sufficient quantity of drug to allow for initiation and completion of the 15-patient confirmatory study. Enrollment of the first patient is expected by the middle of calendar year 2022.\"The enrollment rate in the GBM AGILE Study continues to be robust and is expected to lead to our announcing top-line data for the VAL-083 arm of the study around the end of 2023,\" commented Robert E. Hoffman, Kintara's President and Chief Executive Officer. \"Moving our REM-001 CMBC program back into the clinic is also an important step for us to deliver on our mission of serving cancer patients where there is a clear unmet medical need. We remain on track to st...